Stocklytics Platform
PTC Therapeutics
PTCT62
$52.76arrow_drop_down1.58%-$0.85
PTCT62

$52.76

arrow_drop_down1.58%

Analyst Forecast

no data available for Analyst Forecast

There's no data available for Analyst Forecast

Period: -

• Predicted: -

Analyst Ratings

no data available for Analyst Ratings

There's no data available for Analyst Ratings

Last updated: -

• Total: -

PTC Therapeutics (PTCT) Stocklytics Forecast

PTC Therapeutics Inc (PTCT) is a biopharmaceutical company focused on the development and commercialization of novel treatments for rare genetic disorders. The company's mission is to provide hope to patients and their families by advancing innovative therapies that address the underlying cause of their diseases. With a strong pipeline of potential therapies and a dedicated team of scientists and researchers, PTC Therapeutics is well-positioned for future success.
When it comes to predicting the stock price of PTC Therapeutics Inc, it is important to consider several factors. First and foremost, the company's financial performance and growth prospects play a crucial role in determining its stock price. Investors will closely monitor the company's revenue and earnings growth, as well as its ability to successfully bring new therapies to market. Additionally, market trends and the overall economic climate can also impact the stock price of PTC Therapeutics Inc.
add PTC Therapeutics to watchlist

Keep an eye on PTC Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for PTC Therapeutics (PTCT) stock?

Analysts have set a target price of $34.26 for PTC Therapeutics (PTCT), based on forecasts from 19 analysts. The predicted price range extends from a high of $65 to a low of $17. This represents a potential increase of up to 23.2% and a decrease of -67.78% from the current price of $52.76. These forecasts are as of 2023 Jun 30.
help

What are the analyst ratings for PTC Therapeutics (PTCT) stock?

The analyst ratings for PTC Therapeutics (PTCT) are distributed as follows: 9 analysts recommend buying, 3 have a neutral stance, and 3 suggest selling. There is a split consensus, with equal support for two of the rating categories. These ratings indicate the general sentiment among the analysts covering PTC Therapeutics .
help

What is the AI price prediction for PTC Therapeutics (PTCT) stock?

At present, there is no AI or machine-learning-based price prediction available for PTC Therapeutics (PTCT) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level